Key result
A decrease in B-type natriuretic peptide level of ≥50% during the first 3 months on epoprostenol was strongly predictive of event-free survival (p=0.003).
Why the study?
Does early modulation of B-type natriuretic peptide (BNP) levels predict event-free survival in patients with pulmonary arterial hypertension on epoprostenol therapy?
Population
20 patients with pulmonary arterial hypertension
Design
Cohort
Follow-up
11.0+/-1.8 months
Authors
Loading...
Early BNP reduction may identify lower-risk PAH patients on epoprostenol; hypothesis-generating and requires prospective validation before guiding care.
Cohort (n=20)
Does early modulation of B-type natriuretic peptide (BNP) levels predict event-free survival in patients with pulmonary arterial hypertension on epoprostenol therapy?
p-value: p=0.003
A decrease in BNP of >=50% during the first 3 months of epoprostenol therapy strongly predicts event-free survival in patients with pulmonary arterial hypertension.
Park et al. (2004) conducted a cohort in Pulmonary arterial hypertension (n=20). Decrease in BNP level of ≥50% during the first 3 months vs. No such decrease in BNP level was evaluated on Event-free survival (p=0.003). A decrease in B-type natriuretic peptide level of ≥50% during the first 3 months on epoprostenol was strongly predictive of event-free survival (p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: